The conference is taking place
About
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as 'anticipate,' 'potential,' 'progress,' 'design,' 'estimate,' 'continue,' 'will,' 'aim,' 'can,' 'believe,' 'plan,' 'allow,' 'expect,' 'intend,' 'goal,' 'provide,' 'able to,' 'position,' 'project,' 'developing,' and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: Salarius' growth strategy; the value of seclidemstat as a potential treatment for Ewing sarcoma and other cancers; the status and anticipated progress and milestones of Salarius' clinical trials in advanced solid tumors and Ewing sarcoma; statements related to when and if Salarius will establish maximum tolerated dose in the Ewing sarcoma trial; statements related to when and if Salarius will advance into the dose-expansion phase of the Ewing sarcoma trial; statements related to the expansion of Salarius' clinical trials to include Ewing-related sarcomas; Salarius' developing seclidemstat for several cancers with high unmet medical need; Salarius plans to initiate additional clinical trials; the timing, pursuit and successful execution of milestones in any of Salarius' current or future studies. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the sufficiency of Salarius' capital resources; the ability of, and need for, Salarius to raise additional capital to meet Salarius' business operational needs and to achieve its business objectives and strategy; Salarius' ability to project future capital needs and cash utilization and timing and accuracy thereof; the ability of Salarius to access the remaining funding available under the CPRIT grant; future clinical trial results and impact of results on Salarius; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius' intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions and regulatory or contractual restrictions which may impact the ability of Salarius to raise additional capital; the possibility of unexpected expenses or other uses of Salarius' cash resources; risks related to the COVID-19 outbreak and other risks described in Salarius' filings with the
Contact:
Tel: (212) 375-2664
Email: mmcenroe@tiberend.com
(C) 2021 Electronic News Publishing, source